Sulfobutylether-beta-cyclodextrin (SBECD), a large cyclic oligosaccharide that is used to 2 solubilize voriconazole for intravenous administration, is eliminated mainly by renal excretion.
Voriconazole, a triazole broad spectrum antifungal agent, is used for systemic treatment of severe 2 fungal infections including invasive aspergillosis and invasive candidiasis (7, 10) . For 3 intravenous administration sulfobutylether-beta-cyclodextrin (SBECD) is used as a solvent. 4 SBECD is a cyclic oligosaccharide composed of 1,4-linked glucopyranose molecules that form a 5 truncated cone with a hydrophilic outer surface and a hydrophobic cavity (11, 16 ). This structure 6 leads to an inclusion complex with the lipophilic voriconazole in its center (5). SBECD appears 7 to be well tolerated in humans, but in animal studies, vacuolation of epithelial cells of the urinary 8 tract as well as an activation of macrophages in liver and lung was observed after repeated doses 9 of SBECD (6). SBECD is a pharmacologically inert agent. The terminal half-life of SBECD in 10 humans with normal renal function is 1.8 hours (1) and the steady state volume of distribution is 11 approximately 0.2 l/kg, which is similar to extracellular fluid volume in humans and evidence of 12 very little penetration into tissues (3). SBECD is renally excreted (ninety-five percent of the 13 compound) and its clearance is linearly correlated with creatinine clearance. An increased 14 SBECD exposure has been observed in patients with moderate renal impairment and renal failure 15 (1, 18). Preliminary data from four patients with end-stage renal failure on intermittent 16 hemodialysis indicated an extracorporeal SBECD clearance of 3.3 L/h and removal of 17 approximately 46% of SBECD during four hours of hemodialysis (13). 1 metabolism, which can be described by a 2-compartment model with saturable elimination (9).
2
During hemodialysis solutes are removed by diffusion over a semipermeable membrane whereas 3 in hemofiltration removal of solutes is achieved by convective transport over the membrane by 4 ultrafiltration. In intermittent hemodialysis, as used for patients with end-stage renal disease, a 5 low ultrafiltration rate is used to remove excess water from the body (convective transport of 6 solutes is of limited importance here). In intermittent hemodiafiltration a higher ultrafiltration rate 7 is added, which usually leads to an increase in extracorporeal solute clearance (excessively 8 removed water is replaced in parallel). Genius-dialysis is a special kind of hemodialysis with a 9 single batch system where the whole dialysate is contained in one tank (4). Dialysis settings differ 10 between countries. In Germany dialysis durations of 4 to 5 hours and blood flow rates between 11 200 and 300 ml/min are usually applied whereas in the United States dialysis durations of 3 to 4 12 hours and blood flow rates over 300 ml/min are commonly used (14 Renal replacement therapies. Hemodialysis with the Genius system was performed using a therapy was calculated from the 6 and 6.5 hour concentrations.
10
To estimate the effects of hemodialysis on SBECD disposition at steady-state, pharmacokinetics 11 after repeated doses were predicted based on the parameter values determined in the present study 12 and published values for patients with normal and moderately impaired renal function (1 
RESULTS

7
Fifteen Caucasian patients (9 males, 6 females, mean age 52.6 ± 15.5 years, mean dry weight 8 72.1 ± 18.6 kg) participated in the study. One patient was excluded from analysis due to a dosing 9 error.
10
SBECD was effectively eliminated with half-lives of 2.0 to 2.6 hours ( Figure 1 voriconazole half-lives were very short with 2 to 3 hours and presumably rather reflect 9 distribution than elimination. Thus, the terminal half-life of voriconazole in our patients is 10 unknown and total clearance and apparent volume of distribution could not be calculated. by a 4-hour hemodialysis (3). Unfortunately, the details of the latter study are not available. SBECD elimination in our study was estimated by three different approaches using (1) total 10 plasma clearance (2) the extracorporeal clearance after two and three hours, and (3) the amount of 11 SBECD recovered in dialysate. The clearances calculated in these different ways were 12 consistently ranging between 3.9 L/h (extracorporeal clearance after 2 hours for Genius dialysis) 13 and 6.7 L/h (total plasma clearance of for hemodiafiltration).
14
The observed clearance values in our study were higher than described before, where Extracorporeal clearance values up to 7.1 L/h appear to be high as compared to the average total 7 clearance of voriconazole known from healthy subjects. However, extracorporeal elimination is 8 quantitatively still insignificant due to the large volume of distribution.
9 10
There appears to be a discrepancy for SBECD where plasma-based parameter estimates indicate a 11 more rapid elimination during hemodiafiltration as compared to Genius dialysis whereas 12 dialysate-based values do not. This might be explained by an initially higher clearance by 13 hemodiafiltration that declines more rapidly during the treatment time, e.g. due to formation of a 14 so-called secondary membrane that consists of plasma proteins binding to the dialyzer membrane.
15
The calculated rebound was based on a single concentration 30 minutes after the end of dialysis.
16
Thus, it is possible that we did not capture the full rebound effect. However, the estimation of 17 pharmacokinetic parameters, as applied in the present study, is largely independent from a 18 concentration rebound after the end of dialysis.
19
In the present study voriconazole/SBECD was administered during dialysis (i.e. intradialytic).
20
Intradialytic administration of drugs is rarely used, since unintended drug removal is to be Despite rapid elimination of SBECD by hemodialysis using high-flux membranes it was 8 predicted that SBECD exposure will be still considerably higher after repeated doses because 9 SBECD elimination is "normalized" only intermittently. Thus, a dosing adjustment might be 10 suggested, but this is impossible because of the disparate effects of renal replacement therapy on 11 voriconazole and its solvent. Hence, voriconazole, which is eliminated largely independent from 12 renal function and hemodialysis, has to be administered in regular doses in order to be effective.
13
Therefore, it appears necessary to accept a higher SBECD exposure in patients with renal failure 
Parameter
Genius dialysis Hemodialysis Hemodiafiltration
Based on plasma values
T ½ (h) 2.6 ± 0.6 2.4 ± 0.9 2.0 ± 0.6 
3.9 ± 1.2 4.5 ± 1.5 5.8 ± 0.4
3.9 ± 0.9 4.6 ± 1.7 5.9 ± 0.8 
Parameter Genius dialysis Hemodialysis Hemodiafiltration
Based on plasma values
Voriconazole C max (mg/L) 1.8 ± 0.6 1.7 ± 0.5 1.9 ± 0.5 CL extra,plasma-based,2h (L/h)
3.6 ± 2. 
5.2 ± 1.3 6.0 ± 1.3 6.0 ± 1.4
Based on dialysate values
Voriconazole A extra (%) 8.8 ± 3.3 12.7 ± 3.5 13.1 ± 5.8
A dialysate (mg) 26.6 ± 13.7 37.2 ± 15.3 35.7 ± 15.9** CL extra,dialysate-based (L/h) 4.9 ± 1.5 7.1 ± 1.3 6.9 ± 2.4
Voriconazole-N-oxide
A extra (%) 8.8 ± 7.2 7.7 ± 4.7 9.3 ± 7.6 
